CD274 and neoplasm: The PD-L1 and VISTA-targeted FolTAC-dual degrader is shown to enhance immune activation in an engineered PD-L1 antibody-resistant MC38-C57BL/6 syngeneic mouse model, underscoring its ability to modulate the tumor microenvironment (TME)36–39.